Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 3/20 | 0.37 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.34 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14475269 | 0.93 | KDM4E (0.35) | SCN9AEGFRKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL14474676 | 0.91 | SCN9A (0.43) | SCN9AKDM4ESMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL14474689 | 0.89 | FFAR1 (0.43) | KDM4ESMN1; SMN2S1PR1LMNAGRM5 | |
| SCHEMBL16185145 | 0.88 | GRM5 (0.35) | KLKB1FGFR1FGFR2S1PR1S1PR3 | |
| SCHEMBL16185146 | 0.87 | GRM5 (0.42) | SCN9AKLKB1FGFR1FGFR2EGFR | |
| SCHEMBL14474679 | 0.87 | KLKB1 (0.37) | SCN9AKLKB1FGFR1FGFR2KDM4E | |
| SCHEMBL16185156 | 0.86 | CHRNA7 (0.38) | SCN9AEGFRKDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL16185149 | 0.86 | CHRNA7 (0.38) | SCN9AKLKB1EGFRSMN1; SMN2LMNA | |
| SCHEMBL14474675 | 0.86 | KLKB1 (0.34) | SCN9AKLKB1FGFR1FGFR2EGFR | |
| SCHEMBL14474191 | 0.85 | GRM5 (0.44) | SCN9AEGFRLMNACYP3A4GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2014-10-23 | — | — | US | disclosed |
| WO-2013003586-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140315886-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP2CA, PPP4C, PPP3CB | SCN9A 3217/4885KLKB1 1830/4885FGFR1 1609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.